Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia

Journal of Human Genetics

Volumn 55, Issue 11, 2010, Pages 731-737

  Takahashi, Naoto ^a   Miura, Masatomo ^b   Scott, Stuart A ^c   Kagaya, Hideaki ^b   Kameoka, Yoshihiro ^a   Tagawa, Hiroyuki ^a   Saitoh, Hirobumi ^a   Fujishima, Naohito ^a   Yoshioka, Tomoko ^a   Hirokawa, Makoto ^a   Sawada, Kenichi ^a  

^a AKITA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b AKITA UNIVERSITY HOSPITAL   (Japan)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

ABCG2; chronic myeloid leukemia; imatinib mesylate; pharmacogenetics; single nucleotide polymorphism

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CARRIER PROTEIN; CARRIER PROTEINS AND BINDING PROTEINS; CYTOCHROME P450 3A5; IMATINIB; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; ORGANIC CATION TRANSPORTER 1;

ADULT; AGE; ARTICLE; ASIAN; BODY MASS; CAUCASIAN; CHINESE; CHRONIC MYELOID LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; GENE; GENOTYPE; HUMAN; JAPANESE; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PROTEIN POLYMORPHISM; PROTEIN VARIANT; REGRESSION ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SLCO1B3 GENE; WEIGHT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CYTOCHROME P-450 CYP3A; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PHARMACOGENETICS; PIPERAZINES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN-TYROSINE KINASES; PYRIMIDINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78649522748     PISSN: 14345161     EISSN: None     Source Type: Journal    
DOI: 10.1038/jhg.2010.98     Document Type: Article

References (56)

1. Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031-1037 (2001).
2. Peng, B., Lloyd, P. & Schran, H. Clinical pharmacokinetics of imatinib. Clin. Pharma-cokinet. 44, 879-894 (2005).
3. Cortes, J. E., Egorin, M. J., Guilhot, F., Molimard, M. & Mahon, F. X. Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia. Leukemia. 23, 1537-1544 (2009).
4. Larson, R. A., Druker, B. J., Guilhot, F., O'Brien, S. G., Riviere, G. J., Krahnke, T. et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 111, 4022-4028 (2008).
5. Picard, S., Titier, K., Etienne, G., Teilhet, E., Ducint, D., Bernard, M. A. et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood. 109, 3496-3499 (2007).
6. Kanda, Y., Okamoto, S., Tauchi, T., Kizaki, M., Inokuchi, K., Yabe, M. et al. Multicenter prospective trial evaluating the tolerability of imatinib for Japanese patients with chronic myelogenous leukemia in the chronic phase: does body weight matter? Am. J. Hematol. 83, 835-839 (2008).
7. Sakai, M., Miyazaki, Y., Matsuo, E., Moriuchi, Y., Hata, T., Fukushima, T. et al. Long-term efficacy of imatinib in a practical setting is correlated with imatinib trough concentration that is influenced by body size: a report by the Nagasaki CML Study Group. Int. J. Hematol. 89, 319-325 (2009).
8. Lin, Y. S., Dowling, A. L., Quigley, S. D., Farin, F. M., Zhang, J., Lamba, J. et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal mid-azolam metabolism. Mol. Pharmacol. 62, 162-172 (2002).
9. Williams, J. A., Ring, B. J., Cantrell, V. E., Jones, D. R., Eckstein, J., Ruterbories, K. et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug. Metab. Dispos. 30, 883-891 (2002).
10. Hustert, E., Haberl, M., Burk, O., Wolbold, R., He, Y. Q., Klein, K. et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics. 11, 773-779 (2001).
11. Saeki, M., Saito, Y., Nakamura, T., Murayama, N., Kim, S. R., Ozawa, S. et al. Single nucleotide polymorphisms and haplotype frequencies of CYP3A5 in a Japanese population. Hum. Mutat. 21, 653 (2003).
12. Burger, H., van Tol, H., Boersma, A. W., Brok, M., Wiemer, E. A., Stoter, G. et al. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 104, 2940-2942 (2004).
13. Burger, H. & Nooter, K. Pharmacokinetic resistance to imatinib mesylate: role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinib. Cell Cycle. 3, 1502-1505 (2004).
14. Burger, H., van Tol, H., Brok, M., Wiemer, E. A., de Bruijn, E. A., Guetens, G. et al. Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol. Ther. 4, 747-752 (2005).
15. Choi, M. K. & Song, I. S. Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug. Metab. Pharmacokinet. 23, 243-253 (2008).
16. Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I. & Willingham, M. C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA 84, 7735-7738 (1987).
17. Gurney, H., Wong, M., Balleine, R. L., Rivory, L. P., McLachlan, A. J., Hoskins, J. M. et al. Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype. Clin. Pharmacol. Ther. 82, 33-40 (2007).
18. Gardner, E. R., Burger, H., van Schaik, R. H., van Oosterom, A. T., de Bruijn, E. A., Guetens, G. et al. Association of enzyme and transporter genotypes with the pharma-cokinetics of imatinib. Clin. Pharmacol. Ther. 80, 192-201 (2006).
19. Zhang, L., Schaner, M. E. & Giacomini, K. M. Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell Line (HeLa). J. Pharmacol. Exp. Ther. 286, 354-361 (1998). (Pubitemid 28318011)
20. Zhang, L., Brett, C. M. & Giacomini, K. M. Role of organic cation transporters in drug absorption and elimination. Annu. Rev. Pharmacol. Toxicol. 38, 431-460 (1998).
21. Zhang, L., Dresser, M. J., Gray, A. T., Yost, S. C., Terashita, S. & Giacomini, K. M. Cloning and Functional Expression of a Human Liver Organic Cation Transporter. Mol. Pharmacol. 51, 913-921 (1997).
22. White, D. L., Saunders, V. A., Dang, P., Engler, J., Zannettino, A. C., Cambareri, A. C. et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 108, 697-704 (2006).
23. Wang, L., Giannoudis, A., Lane, S., Williamson, P., Pirmohamed, M. & Clark, R. E. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin. Pharmacol. Ther. 83, 258-264 (2008).
24. Hu, S., Franke, R. M., Filipski, K. K., Hu, C., Orwick, S. J., de Bruijn, E. A. et al. Interaction of imatinib with human organic ion carriers. Clin. Cancer Res. 14, 3141-3148 (2008).
25. Itoda, M., Saito, Y., Maekawa, K., Hichiya, H., Komamura, K., Kamakura, S. et al. Seven novel single nucleotide polymorphisms in the human SLC22A1 gene encoding organic cation transporter 1 (OCT1). Drug. Metab. Pharmacokinet. 19, 308-312 (2004).
26. Zamber, C. P., Lamba, J. K., Yasuda, K., Farnum, J., Thummel, K., Schuetz, J. D. et al. Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics 13, 19-28 (2003).
27. Hirano, M., Maeda, K., Matsushima, S., Nozaki, Y., Kusuhara, H. & Sugiyama, Y. Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol. Pharmacol. 68, 800-807 (2005).
28. Zhang, W., Yu, B. N., He, Y. J., Fan, L., Li, Q., Liu, Z. Q. et al. Role of BCRP 421C4A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin. Chim. Acta. 373, 99-103 (2006).
29. Petain, A., Kattygnarath, D., Azard, J., Chatelut, E., Delbaldo, C., Geoerger, B. et al. Innovative Therapies with Children with Cancer European consortium. Population pharmacokinetics and pharmacogenetics of imatinib in children and adults. Clin. Cancer Res. 14, 7102-7109 (2008).
30. Takahashi, N., Miura, I., Kobayashi, Y., Kume, M., Yoshioka, T., Otane, W. et al. Fluorescence in situ hybridization monitoring of BCR-ABL-positive neutrophils in chronic-phase chronic myeloid leukemia patients during the primary stage of imatinib mesylate therapy. Int. J. Hematol. 81, 235-241 (2005).
31. Yamamoto, M., Kakihana, K., Ohashi, K., Yamaguchi, T., Tadokoro, K., Akiyama, H. et al. Serial monitoring of T315I BCR-ABL mutation by Invader assay combined with RT-PCR. Int. J. Hematol. 89, 482-488 (2009).
32. Bakhtiar, R., Lohne, J., Ramos, L., Khemani, L., Hayes, M. & Tse, F. High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectro-metry. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 768, 325-340 (2002). (Pubitemid 34158868)
33. Parise, R. A., Ramanathan, R. K., Hayes, M. J. & Egorin, M. J. Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 791, 39-44 (2003).
34. Fukuen, S., Fukuda, T., Maune, H., Ikenaga, Y., Yamamoto, I., Inaba, T. et al. Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. Pharmacogenetics 12, 331-334 (2002).
35. Naesens, M., Kuypers, D. R., Verbeke, K. & Vanrenterghem, Y. Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation 82, 1074-1084 (2006).
36. Wu, L., Xu, X., Shen, J., Xie, H., Yu, S., Liang, T. et al. MDR1 gene polymorphisms and risk of recurrence in patients with hepatocellular carcinoma after liver transplantation. J. Surg. Oncol. 96, 62-68 (2007). (Pubitemid 47015450)
37. Tanaka, H., Imamura, N., Oguma, N., Shintani, T., Tanaka, K., Hyodo, H. et al. Acute myelogenous leukemia with PIG-A gene mutation evolved from aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome. Int. J. Hematol. 73, 206-212 (2001).
38. Cascorbi, I., Gerloff, T., Johne, A., Meisel, C., Hoffmeyer, S., Schwab, M. et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin. Pharmacol. Ther. 69, 169-174 (2001).
39. Kobayashi, D., Ieiri, I., Hirota, T., Takane, H., Maegawa, S., Kigawa, J. et al. Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug. Metab. Dispos. 33, 94-101 (2005).
40. Tsujimoto, M., Hirata, S., Dan, Y., Ohtani, H. & Sawada, Y. Polymorphisms and linkage disequilibrium of the OATP8 (OATP1B3) gene in Japanese subjects. Drug. Metab. Pharmacokinet. 21, 165-169 (2006).
41. Gschwind, H. P., Pfaar, U., Waldmeier, F., Zollinger, M., Sayer, C., Zbinden, P. et al. Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug. Metab. Dispos. 33, 1503-1512 (2005).
42. Maliepaard, M., Scheffer, G. L., Faneyte, I. F., van Gastelen, M. A., Pijnenborg, A. C., Schinkel, A. H. et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 61, 3458-3464 (2001).
43. Lepper, E. R., Nooter, K., Verweij, J., Acharya, M. R., Figg, W. D. & Sparreboom, A. Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. Pharmacogenomics 6, 115-138 (2005).
44. Imai, Y., Nakane, M., Kage, K., Tsukahara, S., Ishikawa, E., Tsuruo, T. et al. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol. Cancer Ther. 1, 611-616 (2002).
45. Glaeser, H., Bailey, D. G., Dresser, G. K., Gregor, J. C., Schwarz, U. I., McGrath, J. S. et al. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin. Pharmacol. Ther. 81, 362-370 (2007).
46. Lee, W., Glaeser, H., Smith, L. H., Roberts, R. L., Moeckel, G. W., Gervasini, G. et al. Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. J. Biol. Chem. 280, 9610-9617 (2005).
47. Itoda, M., Saito, Y., Shirao, K., Minami, H., Ohtsu, A., Yoshida, T. et al. Eight novel single nucleotide polymorphisms in ABCG2/BCRP in Japanese cancer patients administered irinotacan. Drug. Metab. Pharmacokinet. 18, 212-217 (2003).
48. Kobayashi, D., Ieiri, I., Hirota, T., Takane, H., Maegawa, S., Kigawa, J. et al. Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug. Metab. Dispos. 33, 94-101 (2005).
49. de Jong, F. A., Marsh, S., Mathijssen, R. H., King, C., Verweij, J., Sparreboom, A. et al. ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin. Cancer Res. 10, 5889-5894 (2004).
50. Mahon, F. X., Belloc, F., Lagarde, V., Chollet, C., Moreau-Gaudry, F., Reiffers, J. et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 101, 2368-2373 (2003).
51. Nakanishi, T., Shiozawa, K., Hassel, B. A. & Ross, D. D. Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression. Blood 108, 678-684 (2006).
52. Jordanides, N. E., Jorgensen, H. G., Holyoake, T. L. & Mountford, J. C. Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. Blood 108, 1370-1373 (2006).
53. Jiang, X., Zhao, Y., Smith, C., Gasparetto, M., Turhan, A., Eaves, A. et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia. 21, 926-935 (2007).
54. Morisaki, K., Robey, R. W., Ozvegy-Laczka, C., Honjo, Y., Polgar, O., Steadman, K. et al. Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemother. Pharmacol. 56, 161-172 (2005).
55. Dulucq, S., Bouchet, S., Turcq, B., Lippert, E., Etienne, G., Reiffers, J. et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 112, 2024-2027 (2008).
56. Kim, D. H., Sriharsha, L., Xu, W., Kamel-Reid, S., Liu, X., Siminovitch, K. et al. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin. Cancer Res. 15, 4750-4758 (2009).